Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease

Makoto Naganuma, Atsushi Sakuraba, Tadakazu Hisamatsu, Hiroki Ochiai, Hirotoshi Hasegawa, Haruhiko Ogata, Yasushi Iwao, Toshifumi Hibi

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: Intestinal Behçet disease (BD) is characterized by intestinal inflammation with round and oval ulcers associated with gastrointestinal symptoms. Although several cases have been reported that infliximab is effective for induction of remission, the efficacy of infliximab for maintaining remission is unknown. Methods: Six cases with fulminant intestinal BD were treated with infliximab. All patients were steroid-dependent and refractory to immunosuppressants; 3 patients were treated with 6-mercaptopurine, 1 patient with azathioprine, 1 patient with cyclosporine A, and 1 patient with methotrexate. Results: Four patients achieved remission by infliximab and all of these patients maintained remission with scheduled treatments of infliximab, with the longest duration of remission being about 3 years. Another 2 patients with ileal ulceration required surgery; however, 1 patient has maintained remission by scheduled treatment of infliximab for 2 years after surgery. Conclusions: Infliximab appears to offer an option for fulminant intestinal BD to induce and maintain remission, although a randomized control trial is needed.

Original languageEnglish
Pages (from-to)1259-1264
Number of pages6
JournalInflammatory Bowel Diseases
Volume14
Issue number9
DOIs
Publication statusPublished - 2008 Sep

Fingerprint

Remission Induction
Intestinal Diseases
Maintenance
Infliximab
6-Mercaptopurine
Azathioprine
Immunosuppressive Agents
Methotrexate
Cyclosporine
Ulcer
Steroids
Inflammation

Keywords

  • Inflimixab
  • Intestinal Behçet's disease
  • Steroid-dependent

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. / Naganuma, Makoto; Sakuraba, Atsushi; Hisamatsu, Tadakazu; Ochiai, Hiroki; Hasegawa, Hirotoshi; Ogata, Haruhiko; Iwao, Yasushi; Hibi, Toshifumi.

In: Inflammatory Bowel Diseases, Vol. 14, No. 9, 09.2008, p. 1259-1264.

Research output: Contribution to journalArticle

Naganuma, Makoto ; Sakuraba, Atsushi ; Hisamatsu, Tadakazu ; Ochiai, Hiroki ; Hasegawa, Hirotoshi ; Ogata, Haruhiko ; Iwao, Yasushi ; Hibi, Toshifumi. / Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. In: Inflammatory Bowel Diseases. 2008 ; Vol. 14, No. 9. pp. 1259-1264.
@article{fb03e4d096f644ceaa224cd7f1097707,
title = "Efficacy of infliximab for induction and maintenance of remission in intestinal Beh{\cc}et's disease",
abstract = "Background: Intestinal Beh{\cc}et disease (BD) is characterized by intestinal inflammation with round and oval ulcers associated with gastrointestinal symptoms. Although several cases have been reported that infliximab is effective for induction of remission, the efficacy of infliximab for maintaining remission is unknown. Methods: Six cases with fulminant intestinal BD were treated with infliximab. All patients were steroid-dependent and refractory to immunosuppressants; 3 patients were treated with 6-mercaptopurine, 1 patient with azathioprine, 1 patient with cyclosporine A, and 1 patient with methotrexate. Results: Four patients achieved remission by infliximab and all of these patients maintained remission with scheduled treatments of infliximab, with the longest duration of remission being about 3 years. Another 2 patients with ileal ulceration required surgery; however, 1 patient has maintained remission by scheduled treatment of infliximab for 2 years after surgery. Conclusions: Infliximab appears to offer an option for fulminant intestinal BD to induce and maintain remission, although a randomized control trial is needed.",
keywords = "Inflimixab, Intestinal Beh{\cc}et's disease, Steroid-dependent",
author = "Makoto Naganuma and Atsushi Sakuraba and Tadakazu Hisamatsu and Hiroki Ochiai and Hirotoshi Hasegawa and Haruhiko Ogata and Yasushi Iwao and Toshifumi Hibi",
year = "2008",
month = "9",
doi = "10.1002/ibd.20457",
language = "English",
volume = "14",
pages = "1259--1264",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease

AU - Naganuma, Makoto

AU - Sakuraba, Atsushi

AU - Hisamatsu, Tadakazu

AU - Ochiai, Hiroki

AU - Hasegawa, Hirotoshi

AU - Ogata, Haruhiko

AU - Iwao, Yasushi

AU - Hibi, Toshifumi

PY - 2008/9

Y1 - 2008/9

N2 - Background: Intestinal Behçet disease (BD) is characterized by intestinal inflammation with round and oval ulcers associated with gastrointestinal symptoms. Although several cases have been reported that infliximab is effective for induction of remission, the efficacy of infliximab for maintaining remission is unknown. Methods: Six cases with fulminant intestinal BD were treated with infliximab. All patients were steroid-dependent and refractory to immunosuppressants; 3 patients were treated with 6-mercaptopurine, 1 patient with azathioprine, 1 patient with cyclosporine A, and 1 patient with methotrexate. Results: Four patients achieved remission by infliximab and all of these patients maintained remission with scheduled treatments of infliximab, with the longest duration of remission being about 3 years. Another 2 patients with ileal ulceration required surgery; however, 1 patient has maintained remission by scheduled treatment of infliximab for 2 years after surgery. Conclusions: Infliximab appears to offer an option for fulminant intestinal BD to induce and maintain remission, although a randomized control trial is needed.

AB - Background: Intestinal Behçet disease (BD) is characterized by intestinal inflammation with round and oval ulcers associated with gastrointestinal symptoms. Although several cases have been reported that infliximab is effective for induction of remission, the efficacy of infliximab for maintaining remission is unknown. Methods: Six cases with fulminant intestinal BD were treated with infliximab. All patients were steroid-dependent and refractory to immunosuppressants; 3 patients were treated with 6-mercaptopurine, 1 patient with azathioprine, 1 patient with cyclosporine A, and 1 patient with methotrexate. Results: Four patients achieved remission by infliximab and all of these patients maintained remission with scheduled treatments of infliximab, with the longest duration of remission being about 3 years. Another 2 patients with ileal ulceration required surgery; however, 1 patient has maintained remission by scheduled treatment of infliximab for 2 years after surgery. Conclusions: Infliximab appears to offer an option for fulminant intestinal BD to induce and maintain remission, although a randomized control trial is needed.

KW - Inflimixab

KW - Intestinal Behçet's disease

KW - Steroid-dependent

UR - http://www.scopus.com/inward/record.url?scp=54349092816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54349092816&partnerID=8YFLogxK

U2 - 10.1002/ibd.20457

DO - 10.1002/ibd.20457

M3 - Article

VL - 14

SP - 1259

EP - 1264

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 9

ER -